SC 0.5 mL/dose. Adult & childn ≥13 yr 2 doses w/ 4-wk min interval. Childn 1-12 yr Administer 1st dose at 12-18 mth. May administer 2nd dose at 4-6 yr. Varicella outbreak Administer 2nd dose before 4 yr w/ at least 3-mth interval from 1st dose. If 1st dose is administered after 12-18 mth, 2nd dose may be administered at ≥4 yr w/ at least 3-mth interval between 1st & 2nd dose.
History of hypersensitivity to live attenuated varicella virus, kanamycin or erythromycin. Fever or malnutrition; CV, renal or hepatic disorder; cellular immunodeficiency; primary, acquired immunodeficiency including, immunosuppression associated w/ AIDS or clinical manifestation of HIV infection; acute myelocytic leukemia, T-cell leukemia or malignant lymphatic tumor. Highly immunosuppressed patients due to RT or intensified treatment for leukemia. History of spasm w/in 1 year prior to administration. Concomitant administration of live vaccines (oral polio, measles, rubella, mumps & BCG) w/in 1 mth. Pregnancy or willingness to conceive w/in 2 mth. Childn <12 mth.
Administer epinephrine when anaphylactoid reaction occurs. Discontinue in case of administration of 6-mercaptopurine for at least 1 wk before vaccination & resume at least 1 wk after vaccination. Avoid close contact of vaccine recipients w/ immunocompromised individuals for up to 6 wk following vaccination. Immunocompromised individuals & pregnant women w/o documented history of varicella or lab evidence of prior infection. Administer w/in 72 hr after exposure to varicella in case of passive immunization by varicella-zoster Ig & done unless there are immunosuppressed symptoms. Pregnancy & lactation.
Not to be given for at least 5 mth following blood or plasma transfusion & any Ig or varicella zoster Ig (VZIG) administration. Not to give Ig including VZIG 2 mth following vaccination. Not to be used w/ salicylates 6 wk following vaccination.
Sign Out
